The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease
Abstract
RATIONALE: Exacerbations of chronic obstructive pulmonary disease (COPD) greatly contribute to declining health status and the progression of the disease, thereby incurring significant direct and indirect health care costs. The prevention of exacerbations, therefore, is an important treatment goal. OBJECTIVES: To assess the impact of combination therapy with salmeterol/fluticasone propionate compared with salmeterol alone on moderate and severe exacerbations in patients with severe COPD and a history of repeated exacerbations. METHODS: Randomized, double-blind, parallel-group study. After a 4-wk run-in period, 994 clinically stable patients were randomized to one of two treatment groups: 507 patients received the salmeterol/fluticasone combination 50/500 micro g twice daily and 487 received salmeterol 50 micro g twice daily for 44 wk. MAIN RESULTS: The total number of exacerbations was 334 in the combination therapy and 464 in the salmeterol group (p < 0.0001). The annualized rate of moderate and severe exacerbations per patient was 0.92 in the combination therapy and 1.4 in the salmeterol group, corresponding to a 35% decrease. In addition, the mean time to first exacerbation in the combination therapy group was significantly longer compared with that of the salmeterol group (128 vs. 93 d, p < 0.0001). Other endpoints, including health-related quality of life, peak expiratory flow, and use of rescue medication, were significantly improved in the combination therapy group. Both treatments were well tolerated. CONCLUSIONS: This study demonstrates that combination therapy with salmeterol/fluticasone compared with salmeterol monotherapy significantly reduces the frequency of moderate/severe exacerbations in patients with severe COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lung volumes and forced ventilatory flows
Quanjer, P. H., Tammeling, G. J., Cotes, J. E., Pedersen, O. F., Peslin, R., & Yernault, J.-C. (1993) · European Respiratory Journal · doi:10.1183/09041950.005s1693 · Cited by 5,318
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07495-8 · Cited by 4,492 · cited 1×
“As a consequence, COPD is expected to become the third most frequent cause of death worldwide by 2020 ( 1 ).”
BackgroundCelli, B. R., MacNee, W., Agusti, A., Anzueto, A., Berg, B., Buist, A. S., Calverley, P. M. A., Chavannes, N., Dillard, T., Fahy, B., et al. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00014304 · Cited by 4,421
(1993) · PubMed · Cited by 3,827
The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary Disease
Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L., Cherniack, R. M., Rogers, R. M., Sciurba, F. C., Coxson, H. O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032158 · Cited by 3,782
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992) · American Review of Respiratory Disease · doi:10.1164/ajrccm/145.6.1321 · Cited by 3,035
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary Disease
SEEMUNGAL, T. A. R., DONALDSON, G. C., PAUL, E. A., BESTALL, J. C., JEFFRIES, D. J., & WEDZICHA, J. A. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.5.9709032 · Cited by 2,312
Donaldson, G. C. (2002) · Thorax · doi:10.1136/thorax.57.10.847 · Cited by 2,272
Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease
Soler-Cataluna, J. J. (2005) · Thorax · doi:10.1136/thx.2005.040527 · Cited by 1,931
Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Anderson, J., & Maden, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12459-2 · Cited by 1,221
Toward a Consensus Definition for COPD Exacerbations
Rodriguez-Roisin, R. (2000) · Chest · doi:10.1378/chest.117.5_suppl_2.398s · Cited by 969
Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00031402 · Cited by 887
Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease
Calverley, P. M., Boonsawat, W., Cseke, Z., Zhong, N., Peterson, S., & Olsson, H. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00027003 · Cited by 730
Interpreting thresholds for a clinically significant change in health status in asthma and COPD
Jones, P. W. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00063702 · Cited by 585
KANNER, R. E., ANTHONISEN, N. R., & CONNETT, J. E. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.3.2010017 · Cited by 583
Efficacy of Salmeterol Xinafoate in the Treatment of COPD
Mahler, D. A., Donohue, J. F., Barbee, R. A., Goldman, M. D., Gross, N. J., Wisniewski, M. E., Yancey, S. W., Zakes, B. A., Rickard, K. A., & Anderson, W. H. (1999) · Chest · doi:10.1378/chest.115.4.957 · Cited by 520
Quality of life changes in COPD patients treated with salmeterol.
Jones, P. W., & Bosh, T. K. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.4.9105068 · Cited by 494
Niewoehner, D. E., Rice, K., Cote, C., Paulson, D., Cooper, J. A. D., Korducki, L., Cassino, C., & Kesten, S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00007 · Cited by 436
Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease
Sin, D. D., Lacy, P., York, E., & Man, S. F. P. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-543oc · Cited by 347
Time course of recovery of health status following an infective exacerbation of chronic bronchitis
Spencer, S. (2003) · Thorax · doi:10.1136/thorax.58.7.589 · Cited by 331
Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease
Donaldson, G. C., Wilkinson, T. M. A., Hurst, J. R., Perera, W. R., & Wedzicha, J. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1054oc · Cited by 316
Hattotuwa, K. L., Gizycki, M. J., Ansari, T. W., Jeffery, P. K., & Barnes, N. C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2105025 · Cited by 270
Economic analysis of the confronting COPD survey: an overview of results
Wouters, E. F. M. (2003) · Respiratory Medicine · doi:10.1016/s0954-6111(03)80020-3 · Cited by 254
Antiinflammatory Effects of Salmeterol/Fluticasone Propionate in Chronic Obstructive Lung Disease
Barnes, N. C., Qiu, Y.-S., Pavord, I. D., Parker, D., Davis, P. A., Zhu, J., Johnson, M., Thomson, N. C., & Jeffery, P. K. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1321oc · Cited by 253
Jones, P. W., Willits, L. R., Burge, P. S., & Calverley, P. M. A. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00013303 · Cited by 249
Hypertension in the elderly. Implications and generalizability of randomized trials
Mulrow, C. D. (1994) · JAMA · doi:10.1001/jama.272.24.1932 · Cited by 225
Lung Mechanics and Dyspnea during Exacerbations of Chronic Obstructive Pulmonary Disease
Stevenson, N. J., Walker, P. P., Costello, R. W., & Calverley, P. M. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-595oc · Cited by 170
The Radiologic Manifestations of Legionnaire's Disease
Tan, M. J., Tan, J. S., File, T. M., Hamor, R. H., & Breiman, R. F. (2000) · Chest · doi:10.1378/chest.117.2.398 · Cited by 166
Suissa, S. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200508-1338pp · Cited by 136
Worth, H., Buhl, R., Cegla, U. H., Criée, C.-P., Gillissen, A., Kardos, P., Köhler, D., MAGNUSSEN, H., Meister, R., Nowak, D., et al. (2002) · Pneumologie · doi:10.1055/s-2002-35553 · Cited by 126
Self-citationAaron, S. D., Vandemheen, K. L., Clinch, J., Ahuja, J., Brison, R. J., Dickinson, G. E., & Hébert, P. C. (2002) · CHEST Journal · doi:10.1378/chest.121.3.688 · Cited by 124
Addition of salmeterol to existing treatment in patients with COPD: a 12 month study
STOCKLEY, R. A., Chopra, N., & Rice, L. (2006) · Thorax · doi:10.1136/thx.2004.033266 · Cited by 97
Nannini, L. J., Cates, C. J., Lasserson, T., & Poole, P. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003794.pub2 · Cited by 94
Yıldız, F., Kaur, A., Ilgazlı, A., et al. (2000) · Respiration · doi:10.1159/000029466 · Cited by 61
Update in Chronic Obstructive Pulmonary Disease 2005
Fabbri, L. M., Luppi, F., Beghé, B., & Rabe, K. F. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2603005 · Cited by 61
Cited by
O’Donnell, D. E., Aaron, S., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M., Ford, G., Gervais, A., Goldstein, R., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Bafadhel, M., McKenna, S., Terry, S., Mistry, V., Pancholi, M., Venge, P., Lomas, D. A., Barer, M. R., Johnston, S. L., Pavord, I. D., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1553oc · Cited by 612
Inhaled corticosteroids in COPD and the risk of serious pneumonia
Suissa, S., Patenaude, V., Lapi, F., & Ernst, P. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202872 · Cited by 444
The clinical and economic burden of chronic obstructive pulmonary disease in the USA
Ray, S., Guarascio, Finch, & Self, T. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s34321 · Cited by 425
Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., & Kessler, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200904-0492oc · Cited by 408
Metadata
- Authors
- Kardos, P., Wencker, M., Glaab, T., & Vogelmeier, C.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-15
- Volume
- 175
- Issue
- 2
- Pages
- 144-149
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2158714986
- Cited by
- 314
- References
- 39
- FWCI
- 23.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.